News
DSNKY
18.86
-0.21%
-0.04
Weekly Report: what happened at DSNKY last week (0914-0918)?
Weekly Report · 1d ago
Merck, Astra, Roche and Corcept among winners of EU drug recommendations this week
Seeking Alpha · 3d ago
Astra-Daiichi breast cancer drug Enhertu recommended for NHS use in England
Seeking Alpha · 4d ago
AstraZeneca, Daiichi Drug Has Good Lung-Cancer Data, But Competition Awaits -- Market Talk
Dow Jones · 09/14 14:50
Weekly Report: what happened at DSNKY last week (0907-0911)?
Weekly Report · 09/14 09:20
Reported Earlier, AstraZeneca And Daiichi Sankyo's Enhertu Cuts Risk Of Disease Progression Or Death By 37.0% Versus Pembrolizumab Plus Chemotherapy In Phase III Trial
Benzinga · 09/14 05:32
Weekly Report: what happened at DSNKY last week (0831-0904)?
Weekly Report · 09/07 09:18
Astra, Daiichi granted EU nod for Enhertu in first-line breast cancer
Seeking Alpha · 09/01 16:15
Weekly Report: what happened at DSNKY last week (0824-0828)?
Weekly Report · 08/31 09:20
Weekly Report: what happened at DSNKY last week (0817-0821)?
Weekly Report · 08/24 09:20
Tempus AI Just Had Their Entire Strategy Validated By Moderna's Vaccine Advance
Seeking Alpha · 08/20 12:00
Weekly Report: what happened at DSNKY last week (0810-0814)?
Weekly Report · 08/17 09:20
Daiichi Sankyo And AstraZeneca's Enhertu Shows Significant PFS Improvement As First-Line HER2 Mutant NSCLC Treatment In DESTINY-Lung04 Phase 3 Trial
Benzinga · 08/17 06:54
Weekly Report: what happened at DSNKY last week (0803-0807)?
Weekly Report · 08/10 09:19
AstraZeneca tops pharma growth rankings while Bristol Myers trails amid merger talks
Seeking Alpha · 08/03 12:11
Weekly Report: what happened at DSNKY last week (0727-0731)?
Weekly Report · 08/03 09:19
AstraZeneca and Daiichi win EU label expansion for Datroway in breast cancer
Seeking Alpha · 07/31 10:53
Daiichi Sankyo Company reports Q1 results
Seeking Alpha · 07/31 10:06
Daiichi Sankyo Co Lowers FY2026 GAAP EPS Guidance from $0.91 to $0.87 vs $1.04 Est; Raises FY2026 Sales Guidance from $14.537B to $14.684B vs $13.370B Est
Benzinga · 07/31 08:05
EU Approves Daiichi Sankyo And AstraZeneca's Datroway For First-Line Metastatic TNBC, Showing 5.0 Month Overall Survival Improvement Over Chemotherapy In TROPION-Breast02 Trial
Benzinga · 07/31 07:25
More
Webull provides a variety of real-time DSNKY stock news. You can receive the latest news about Daiichi Sankyo through multiple platforms. This information may help you make smarter investment decisions.
About DSNKY
Daiichi Sankyo Co Ltd is a Japan-based company mainly engaged in the manufacture and sale of pharmaceuticals. The Company is involved in the research, development, manufacture and sale of pharmaceuticals, as well as the provision of intermediates and basic materials for pharmaceutical producing in Japan, the United States, Europe and other markets. The Company is also engaged in the research, development, manufacture and sale of over-the-counter drugs and vaccines, the provision of administrative services such as human resources and accounting services, real estate leasing and insurance agency business.